Sun Pharma falls on anti-diabetes drug recall

Shares in Sun Pharmaceutical Industries Ltd fall as much as 2.8 percent after the

RELATED ARTICLES

US Food and Drug Administration said the drug maker was voluntarily recalling 2,528 bottles of its generic version of diabetes drug Glumetza from US-based Santarus Inc.

Sun began recalling the bottles of metformin HCL extended-release tables in the United States on January 28, 2014, after it received a customer complaint that one of the bottles contained tablets of epilepsy drug Gabapentin, the FDA said in a release on its web site.

A Sun spokeswoman confirmed the recall on Monday morning, adding that the company did not expect a significant impact.

The FDA classified the recall as a "Class II," which signifies a remote chance of severe adverse consequences or death due to the product flaw.

The Sun recall comes as shares in Ranbaxy Laboratories Ltd fell as much as 3.8 percent on Monday after the drug maker recalled more than 64,000 bottles of the generic version of a cholesterol-lowering drug in the United States after a doseage mix-up was detected.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • It’s another challenging year for a govt that’s missed 20 of 24 targets

    The government has set an ambitious target for money to be raised through sale of public sector company shares.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Taslima Nasreen

Will Saudi sex slavery ever end?

An intriguing news item was published in the Arab world ...

Purnendu Ghosh

Err all right, but hiding is wrong

We are human, and therefore, prone to making mistakes. We ...

Shona Adhikari

Art lovers in India are spoilt for choice

Recent art trends point towards the inclusion of a wider ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture